Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Trimetrexate: experience with solid tumors

D G Haller1

  • 1Department of Medicine, University of Pennsylvania Cancer Center, The University of Pennsylvania School of Medicine, Philadelphia 19104, USA.

Seminars in Oncology
|January 7, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis.

ESMO open·2025
Same author

Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009.

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer.

Journal of surgical oncology·2007
Same author

A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.

British journal of cancer·2005
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
Same journal

Stoma-free precision sphincter-preserving surgery with J-pouch for metastatic low rectal neuroendocrine tumor.

Seminars in oncology·2026
See all related articles

Trimetrexate (TMTX) shows antitumor activity in various cancers, including breast and lung. Further research into TMTX combination therapy with 5-fluorouracil/leucovorin is recommended.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Trimetrexate (TMTX) is a dihydrofolate reductase inhibitor, similar to methotrexate (MTX).
  • Differences between TMTX and MTX necessitate evaluating TMTX in both MTX-sensitive and resistant tumors.

Purpose of the Study:

  • To review the antitumor activity of single-agent Trimetrexate (TMTX).
  • To explore the potential of TMTX in combination therapy, particularly with 5-fluorouracil/leucovorin.

Main Methods:

  • Review of Phase II clinical trials assessing single-agent TMTX activity.
  • Analysis of TMTX's biochemical modulation effects on other chemotherapeutic agents.

Main Results:

  • Variable antitumor activity of single-agent TMTX observed across diverse patient populations and treatment schedules.

Related Experiment Videos

  • Documented single-agent activity in breast, non-small cell lung, head and neck, urothelial, prostate, and gastric cancers.
  • Suggested clinical activity in pediatric renal cell carcinoma.

    • Conclusions:

    • Trimetrexate (TMTX) exhibits single-agent activity in several common and rare tumor types.
    • TMTX's role as a biochemical modulator of 5-fluorouracil/leucovorin supports further investigation in combination therapy.
    • Combination therapy with TMTX is attractive due to its potential dual role in exhibiting direct antitumor effects and enhancing other agents.